EUVIMEDEUVIMED entdecken
Leserbrief

Quizartinib for Newly Diagnosed FLT3 -Internal Tandem Duplication–Negative AML

Motoharu Shibusawa iD, Tetsuya Tanimoto iD

Journal of Clinical Oncology · 10.06.2026 · 44 (17) · 1648-1648

DOI: 10.1200/jco-25-02702 ↗

Kurz gefasst

Leserbrief in der Zeitschrift Journal of Clinical Oncology, erschienen am 10.06.2026. Verfasst von Motoharu Shibusawa und 1 weiteren Autor:innen. Beteiligte Einrichtung: Motoharu Shibusawa, MD, Sanaikai General Hospital, Saitama, Japan; and Tetsuya Tanimoto, MD, Medical Governance Research Institute, Tokyo, Japan. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 5 Literaturangaben.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Autor:innen und Institutionen

  • Motoharu Shibusawa, MD, Sanaikai General Hospital, Saitama, Japan; and Tetsuya Tanimoto, MD, Medical Governance Research Institute, Tokyo, Japan.

ORCID-Profile: Motoharu Shibusawa, Tetsuya Tanimoto

Zitieren

APA

Shibusawa, M., & Tanimoto, T. (2026). Quizartinib for Newly Diagnosed FLT3 -Internal Tandem Duplication–Negative AML. Journal of Clinical Oncology, 44(17), 1648-1648. https://doi.org/10.1200/jco-25-02702

Vancouver

Shibusawa M, Tanimoto T. Quizartinib for Newly Diagnosed FLT3 -Internal Tandem Duplication–Negative AML. Journal of Clinical Oncology. 2026;44(17):1648-1648. doi:10.1200/jco-25-02702

BibTeX
@article{Shibusawa2026,
  author = {Shibusawa, Motoharu and Tanimoto, Tetsuya},
  title = {Quizartinib for Newly Diagnosed FLT3 -Internal Tandem Duplication–Negative AML},
  journal = {Journal of Clinical Oncology},
  year = {2026},
  volume = {44},
  number = {17},
  pages = {1648--1648},
  doi = {10.1200/jco-25-02702}
}
Kostenlos starten →